Pharmaceutical firm Bayer has lost its legal fight to overturn the Indian government’s decision to allow Natco Pharma to produce its cancer drug Nexavar under compulsory licence.
The Intellectual Property Appellate Board (IPAB) in Chennai upheld the landmark decision made last March by the comptroller of patents citing the high cost of the medication. Nexavar is used in the treatment of liver and kidney cancer and was sold by Bayer for Rs.280,000 (£3,380) per month while Natco is selling the drug for only…
This content is for subscribers only. Subscribe now for free to read the full article.
Already a subscriber? Login
